Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00115011
Status:
COMPLETED
Last Update Posted:
2008-05-20
First Post:
2005-06-20
Brief Title:
Escitalopram for the Treatment of Self-Injurious Skin Picking
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
Escitalopram for the Treatment of Self-Injurious Skin Picking
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effectiveness of escitalopram in treating self-injurious skin picking
Detailed Description:
Purpose Self-injurious skin picking is a problem documented to occur in 2 of dermatology patients Gupta Gupta and Haberman 1986 and approximately 4 of the general population Keuthen et al 2000 It is widely under recognized with medical sequelae that can include scarring infections lesions and potentially life-threatening outcomes OSullivan et al 1999 In a prior study fluoxetine was shown to be superior to placebo in treating self-injurious skin picking in a modest-sized double blind trial Simeon et al 1997 Similarly open-label trials of other SSRIs including sertraline Kalivas Kalivas and Gilman 1996 and fluvoxamine Arnold et al 1999 resulted in reductions in skin-picking behavior Escitalopram is a new SSRI that may have superior efficacy for the treatment of major depression and fewer side effects than other SSRIs This study aims to assess the efficacy of escitalopram in patients who suffer from self-injurious skin-picking
Comparisons Subjects initial scores on the CGI HAM-D SPTS SPS SPIS BDI BAI QLESQ BDDQ will be compared to subjects final scores
Comparisons Subjects initial scores on the CGI HAM-D SPTS SPS SPIS BDI BAI QLESQ BDDQ will be compared to subjects final scores
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1200-211220 | None | None | None |
| LXP-MD-36 | None | None | None |